Soft tissue sarcoma (STS) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-COSTELLO-CARRIER-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-19 \| pending_clinical_signoff
Diseases	`DIS-SOFT-TISSUE-SARCOMA`
Sources	`SRC-ESMO-SARCOMA-2024` `SRC-NCCN-BLADDER-2025` `SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025`

Notes

STUB pending two-Co-Lead signoff per CHARTER §6.1 dev-mode. Standard-track Costello-syndrome confirmed-carrier surveillance per Gripp / Costello Syndrome Family Network consensus. Disease anchor DIS-SOFT-TISSUE-SARCOMA covers embryonal RMS; neuroblastoma + bladder TCC cancer-spectrum noted in rationale.

Used By

Indication

IND-COSTELLO-CARRIER-INTENSIFIED - IND-COSTELLO-CARRIER-INTENSIFIED